Matus Studeny

3.6k total citations · 3 hit papers
37 papers, 2.9k citations indexed

About

Matus Studeny is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matus Studeny has authored 37 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 11 papers in Genetics and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matus Studeny's work include Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Mesenchymal stem cell research (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Matus Studeny is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Mesenchymal stem cell research (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Matus Studeny collaborates with scholars based in United States, Germany and France. Matus Studeny's co-authors include Michael Andreeff, Frank C. Marini, Claudia Zompetta, Jennifer L. Dembinski, Richard E. Champlin, Isaiah J. Fidler, F. Marini, M. Andreeff, Maria da Graça Cabreira-Hansen and Richard Champlin and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Matus Studeny

36 papers receiving 2.9k citations

Hit Papers

Human Bone Marrow–Derived Mesenchymal Stem Cells in the T... 2002 2026 2010 2018 2005 2002 2004 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
    2005 869 citations Frank C. Marini, Matus Studeny et al. profile →
  2. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.
    2002 768 citations Matus Studeny, Frank C. Marini et al. PubMed profile →
  3. Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents
    2004 670 citations Matus Studeny, F. Marini et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matus Studeny United States 17 1.6k 1.3k 1.2k 585 485 37 2.9k
Erika L. Spaeth United States 18 1.8k 1.2× 1.9k 1.4× 1.6k 1.3× 395 0.7× 864 1.8× 33 4.0k
Joy Gumin United States 28 1.5k 0.9× 1.2k 0.9× 1.9k 1.6× 575 1.0× 1.0k 2.1× 74 3.7k
Ajeeta B. Dash United States 11 1.0k 0.7× 1.8k 1.4× 1.6k 1.3× 169 0.3× 808 1.7× 23 3.6k
Ross Tubo United States 17 1.1k 0.7× 1.6k 1.2× 1.4k 1.1× 200 0.3× 759 1.6× 19 3.7k
Venkata Lokesh Battula United States 21 1.3k 0.8× 1.0k 0.8× 1.4k 1.1× 144 0.2× 573 1.2× 60 3.0k
G Paradis United States 6 798 0.5× 1.2k 0.9× 1.7k 1.4× 241 0.4× 364 0.8× 7 3.2k
Giacomo G. Vecil United States 11 769 0.5× 520 0.4× 679 0.6× 336 0.6× 253 0.5× 17 1.6k
Kent Claypool United States 6 590 0.4× 1.4k 1.0× 1.2k 1.0× 95 0.2× 532 1.1× 6 2.5k
Nduka Amankulor United States 21 943 0.6× 641 0.5× 791 0.6× 128 0.2× 510 1.1× 56 2.4k
Anja Seckinger Germany 33 1.6k 1.0× 984 0.7× 2.3k 1.9× 151 0.3× 348 0.7× 115 4.2k

Countries citing papers authored by Matus Studeny

Since Specialization
Citations

This map shows the geographic impact of Matus Studeny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matus Studeny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matus Studeny more than expected).

Fields of papers citing papers by Matus Studeny

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matus Studeny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matus Studeny. The network helps show where Matus Studeny may publish in the future.

Co-authorship network of co-authors of Matus Studeny

This figure shows the co-authorship network connecting the top 25 collaborators of Matus Studeny. A scholar is included among the top collaborators of Matus Studeny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matus Studeny. Matus Studeny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wermke, Martin, Valentina Gambardella, Yasutoshi Kuboki, et al.. (2025). Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. Journal of Clinical Oncology. 43(27). 3021–3031. 4 indexed citations
2.
Wermke, Martin, Valentina Gambardella, Yasutoshi Kuboki, et al.. (2024). OA10.05 Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC. Journal of Thoracic Oncology. 19(10). S32–S32. 1 indexed citations
3.
Wermke, Martin, Valentina Gambardella, Yasutoshi Kuboki, et al.. (2024). 670P Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data. Annals of Oncology. 35. S525–S526. 7 indexed citations
4.
Kuboki, Yasutoshi, Valentina Gambardella, Olatunji B. Alese, et al.. (2023). 75MO Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts. Annals of Oncology. 34. S1495–S1495.
5.
Wermke, Martin, Yasutoshi Kuboki, Enriqueta Felip, et al.. (2023). OA01.05 Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+ Tumors: Focus on SCLC. Journal of Thoracic Oncology. 18(11). S45–S46. 3 indexed citations
6.
Gambardella, Valentina, Yasutoshi Kuboki, Olatunji B. Alese, et al.. (2023). 725MO Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas. Annals of Oncology. 34. S499–S500. 2 indexed citations
7.
Кunelskaya, N. L., et al.. (2020). Cardiac arrest in obstructive sleep apnea syndrome: treatment options. Case series. Russian Bulletin of Otorhinolaryngology. 85(4). 43–43. 1 indexed citations
8.
Palmer, Daniel H., Yuk Ting, Markus Peck‐Radosavljevic, et al.. (2018). A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. British Journal of Cancer. 118(9). 1162–1168. 26 indexed citations
9.
Cutsem, Eric Van, Takayuki Yoshino, Heinz‐Josef Lenz, et al.. (2018). Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Annals of Oncology. 29(9). 1955–1963. 49 indexed citations
10.
11.
Cutsem, Eric Van, Hans Prenen, Geert D’Haens, et al.. (2015). A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. Annals of Oncology. 26(10). 2085–2091. 35 indexed citations
12.
13.
Cutsem, E. Van, Josep Tabernero, Takayuki Yoshino, et al.. (2014). Lume-Colon 1: Double-Blind, Randomised Phase III Study of Nintedanib (Bibf 1120) Plus Best Supportive Care (Bsc) Versus Placebo Plus Bsc in Patients (Pts) with Refractory Colorectal Cancer. Annals of Oncology. 25. iv208–iv208. 1 indexed citations
14.
Mross, K., Martin Büchert, Annette Frost, et al.. (2014). Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. BMC Cancer. 14(1). 510–510. 26 indexed citations
15.
Yen, Clarence, Yee Chao, Lin Deng, et al.. (2013). Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial. European Journal of Cancer. 49. 5 indexed citations
16.
Dembinski, Jennifer L., Erika L. Spaeth, Matus Studeny, et al.. (2013). Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy. 15(1). 20–32.e2. 53 indexed citations
17.
Dembinski, Jennifer L., Erika L. Spaeth, Juàn Fueyo, et al.. (2009). Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Therapy. 17(4). 289–297. 48 indexed citations
18.
Hall, Brett M., Jennifer L. Dembinski, A. Kate Sasser, et al.. (2007). Mesenchymal Stem Cells in Cancer: Tumor-Associated Fibroblasts and Cell-Based Delivery Vehicles. International Journal of Hematology. 86(1). 8–16. 138 indexed citations
19.
Studeny, Matus, Frank C. Marini, Richard E. Champlin, et al.. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.. PubMed. 62(13). 3603–8. 768 indexed citations breakdown →
20.
Verhagen, A., Matus Studeny, Gert Luurtsema, et al.. (1994). Metabolism of a [18F]fluorine labeled progestin (21 -[18F]fluoro-16α -ethyl-19-norprogesterone) in humans: a clue for future investigations. Nuclear Medicine and Biology. 21(7). 941–952. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erika L. Spaeth Breakdown of academic impact, for papers by Joy Gumin Breakdown of academic impact, for papers by Ajeeta B. Dash Breakdown of academic impact, for papers by Ross Tubo Breakdown of academic impact, for papers by Venkata Lokesh Battula Breakdown of academic impact, for papers by G Paradis Breakdown of academic impact, for papers by Giacomo G. Vecil Breakdown of academic impact, for papers by Kent Claypool Breakdown of academic impact, for papers by Nduka Amankulor Breakdown of academic impact, for papers by Anja Seckinger
Rankless by CCL
2026